Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management

Figure 1

T-cell targets for immunoregulatory antibody therapy [10]; reproduced with permission from Mellman et al. 2011 [10].